Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab
New patent expands protection for mitazalimab in Europe Patent protects composition of matter for mitazalimab until 2038 (including potentia ...
Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy”
ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on ...
Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...
Alligator Bioscience Presents New Data Demonstrating Durable Response and Encouraging Anti-Tumor Activity of Lead Asset Mitazalimab
Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha ...
Alligator Bioscience Announces Publication Highlighting Pharmacodynamic Data from Mitazalimab Phase 1 Study in Scientific Journal “Cells”
Data demonstrate that mitazalimab induces transcriptomic alterations consistent with immune activation Data reinforce mitazalimab's mod ...
Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...
The exercise period for Alligator’s warrants of series TO 6 begins today
Today, on August 17, 2023, the exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) ("Alligator" or the ...
Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer
Lund, Sweden, August 17, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as th ...
Exercise price determined for the exercise of warrants of series TO 6 in Alligator Bioscience AB
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series TO 6 (the “warran ...